Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
C5a anaphylatoxin is a major regulator of activating versus inhibitory FcγRs in immune complex–induced lung disease
Nelli Shushakova, … , Reinhold E. Schmidt, J. Engelbert Gessner
Nelli Shushakova, … , Reinhold E. Schmidt, J. Engelbert Gessner
Published December 15, 2002
Citation Information: J Clin Invest. 2002;110(12):1823-1830. https://doi.org/10.1172/JCI16577.
View: Text | PDF
Article Autoimmunity

C5a anaphylatoxin is a major regulator of activating versus inhibitory FcγRs in immune complex–induced lung disease

  • Text
  • PDF
Abstract

Research Article

Authors

Nelli Shushakova, Julia Skokowa, Jurriaan Schulman, Ulrich Baumann, Jörg Zwirner, Reinhold E. Schmidt, J. Engelbert Gessner

×

Figure 8

Options: View larger image (or click on image) Download as PowerPoint
FACS analysis of FcγRII/III surface expression in IC-challenged mice. Pr...
FACS analysis of FcγRII/III surface expression in IC-challenged mice. Protein expression of the inhibitory/activating FcγRII/III receptor pair was assessed in BAL-AM cells from indicated mice obtained 2 hours after OVA/anti-OVA challenge (ICs). Mice not receiving the OVA antigen served as Ab control (Ab). (a–c) Representative results of individual mice are shown. (a) AM cells were stained with PE anti-FcγRII/III 2.4G2 mAb. Different FcγRII/III staining patterns are specifically observed in FcγRII–/– and FcγRIII–/– mice after IC challenge (solid line, IC) as compared with Ab control (dashed line, Ab), demonstrating inverse regulation of surface expression of inhibitory FcγRII (reduced) and activating FcγRIII (increased) by ICs. (b) AM cells from WT or C5aR–/– mice were stained with the anti-FcγRII mAb Ly17.2 conjugated to FITC. Note the IC-induced suppression of surface FcγRII in WT but not C5aR–/– mice. (c) In order to achieve FcγRIII specificity, AM cells were first treated with unlabeled anti-FcγRII Ly17.2 mAb (Ly17.2 blockade) followed by PE-2.4G2 mAb staining. Substantial IC-induced upregulation of surface FcγRIII was detected in WT mice but is impaired in C5aR–/– mice.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts